<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03869385</url>
  </required_header>
  <id_info>
    <org_study_id>ZKSJ0112_ARISS</org_study_id>
    <secondary_id>2018-001874-89</secondary_id>
    <secondary_id>SA 2167/3-1, Nr: 328809707</secondary_id>
    <secondary_id>ZKSJ0112</secondary_id>
    <nct_id>NCT03869385</nct_id>
  </id_info>
  <brief_title>Albumin Replacement Therapy in Septic Shock</brief_title>
  <acronym>ARISS</acronym>
  <official_title>Randomised Controlled Multicentre Study of Albumin Replacement Therapy in Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jena University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Grifols, S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Goettingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SepNet - Critical Care Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Sepsis Control and Care, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Center for Clinical Trials (ZKS), Jena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jena University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Albumin is a key regulator of fluid distribution within the extracellular space and possesses&#xD;
      several properties beyond its oncotic activity, including binding and transport of several&#xD;
      endogenous molecules, anti-inflammatory and anti-oxidant actions, nitric oxide modulation,&#xD;
      and buffer function. The accumulating evidence suggests that supplementation of albumin may&#xD;
      provide survival advantages only when the insult is severe as in patients with septic shock.&#xD;
      Prospective randomized trials on the possible impact of albumin replacement in these patients&#xD;
      with septic shock are lacking. The aim of the study is to investigate whether the replacement&#xD;
      with albumin and the maintenance of its serum levels at least at 30 g/l for 28 days improve&#xD;
      survival in patients with septic shock compared to resuscitation and volume maintenance&#xD;
      without albumin. In this prospective, multicenter, randomised trial, adult patients (≥18&#xD;
      years) with septic shock will be randomly assigned within a maximum of 24 hours after the&#xD;
      onset of septic shock after obtaining informed consents to treatment or control groups.&#xD;
      Patients assigned to the treatment group will receive a 60 g loading dose of human albumin&#xD;
      20% over 2-3 hours. Serum albumin levels will be maintained at least at 30 g/l in the ICU for&#xD;
      a maximum of 28 days following randomization using 40-80 g human albumin 20% infusion. The&#xD;
      control group will be treated according to the usual practice with crystalloids as the first&#xD;
      choice for the resuscitation and maintenance phase of septic shock. The primary end point is&#xD;
      90 days mortality and secondary end points include 28-day, 60-day, ICU, and in-hospital&#xD;
      mortality, organ dysfunction/failure, and length of ICU and hospital stay. In total 1412&#xD;
      patients need to be analyzed, 706 per group. Assuming a dropout rate of 15%, a total of 1662&#xD;
      patients need to be allocated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicentre, randomised, controlled, parallel-grouped, open-label,&#xD;
      interventional clinical trial in which 1662 patients are planned to be allocated. Subjects&#xD;
      will be randomized in a 1:1 ratio to receive either Albumin or routine treatment with&#xD;
      crystalloids. Treatment will be continued at maximum for 28 days or until the patient leaves&#xD;
      the ICU. Primary endpoint measurement will be carried out 90 days after randomisation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>90-day all cause mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Mortality within 90 days after randomisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Mortality within 28 days after randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>60-day mortality</measure>
    <time_frame>60 days</time_frame>
    <description>Mortality within 60 days after randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ failure</measure>
    <time_frame>28 days</time_frame>
    <description>Organ failure defined as increase in the daily recorded Sequential organ Failure Assessement (SOFA) subscores; cardiovascular, respiratory, hematologic, hepatic, renal, neurologic (range 0-4 points each) from a value &lt;2 to a value ≥ 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessement (SOFA) score</measure>
    <time_frame>28 days</time_frame>
    <description>The overall degree of organ dysfunction/failure assessed daily by the total SOFA score (range 0-24 points), with higher scores indicating higher degree of overall organ dysfunction/failure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>90 days</time_frame>
    <description>ICU stay of first hospitalization after randomisation within 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>90 days</time_frame>
    <description>Hospital stay of first hospitalization after randomisation within 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilation-free days</measure>
    <time_frame>28 days</time_frame>
    <description>Ventilation-free days within 28 days after randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor-free days</measure>
    <time_frame>28 days</time_frame>
    <description>Vasopressor-free days within 28 days after randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount of fluid of fluid administration and total fluid balance in the ICU.</measure>
    <time_frame>28 days</time_frame>
    <description>Total amount of fluid of fluid administration and total fluid balance in the ICU within 28 days after randomisation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1662</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Albumin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to the Albumin group will receive a 60 g loading dose of human albumin 20% over 2-3 hours. Serum albumin levels will be maintained at least at 30 g/l in the ICU for a maximum of 28 days following randomization using 40-80 g human albumin 20% infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group without albumin:</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will be treated according to the usual practice with crystalloids as the first choice for the resuscitation and maintenance phase of septic shock.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albutein® 200 g/L or Plasbumin® 20</intervention_name>
    <description>The initial dose of the trial drug must be started within 6 to 24 hours after the beginning of the septic shock. Starting dose: 60 g human albumin 20% (Albutein® 200 g/L, infusion solution) over 2-3 h Daily administration of the trial drug will be based on the serum albumin concentration measured each day. Dose adjustment will follow a predetermined schedule with the aim of maintaining a serum albumin concentration of at least 30 g/l. Administration of the trial drug will continue for a maximum of 28 study days after randomisation and only as long as the participant is being treated in the ICU.</description>
    <arm_group_label>Albumin group</arm_group_label>
    <other_name>Human Albumin 20%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The presence of septic shock meeting all of the following criteria:&#xD;
&#xD;
               -  Clinically possible or probable or microbiologically confirmed infection taking&#xD;
                  into account the definitions of the &quot;International Sepsis Forum (ISF)&quot;&#xD;
&#xD;
               -  Despite adequate volume therapy, vasopressors are required to maintain mean&#xD;
                  arterial pressure (MAP) ≥ 65 mm Hg for at least 1 hour&#xD;
&#xD;
               -  Serum lactate level &gt; 2 mmol/l (18 mg/dl) despite adequate volume therapy&#xD;
&#xD;
          -  Start of septic shock less than 24 hours prior to inclusion, so that the start dose of&#xD;
             the trial drug in the albumin group will be possible within 6-24 hours after the start&#xD;
             of the septic shock&#xD;
&#xD;
          -  Age: ≥ 18 years&#xD;
&#xD;
          -  Written informed consent of the patient or his/her legal representative or&#xD;
             confirmation of the urgency of participation in the clinical trial and possible&#xD;
             benefit to the patient by an independent consultant or the implementation of other&#xD;
             established procedures according to the local regulations of the contributing centre&#xD;
             to include patients who are unable to provide informed consent in whom subsequent&#xD;
             consent may be obtained retrospectively.&#xD;
&#xD;
          -  Patients of childbearing age: negative pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Moribund conditions with life expectancy less than 28 days because of comorbid&#xD;
             conditions or advanced malignant disease and palliative situations with life&#xD;
             expectancy less than 6 months&#xD;
&#xD;
          -  Presence of an &quot;end of life&quot; decision prior to obtaining informed consent: &quot;Do Not&#xD;
             Resuscitate (DNR)&quot; and &quot;Withhold/Withdraw Life-Sustaining measures&quot;&#xD;
&#xD;
          -  Previous participation in this study&#xD;
&#xD;
          -  Participation in another interventional clinical trial within the past 3 months&#xD;
&#xD;
          -  Shock states that can be explained by other causes, e.g. cardiogenic shock,&#xD;
             anaphylactic shock, neurogenic shock&#xD;
&#xD;
          -  History of hypersensitivity to albumin or any other component of the trial drug, e.g.,&#xD;
             B., sodium caprylate, sodium N-acetyltryptophanate&#xD;
&#xD;
          -  Diseases in which albumin administration may be deleterious, e.g., decompensated heart&#xD;
             failure or traumatic brain injury&#xD;
&#xD;
          -  Clinical conditions where albumin administration is indicated, e.g., hepatorenal&#xD;
             syndrome, nephrosis, burns, intestinal malabsorption syndrome&#xD;
&#xD;
          -  Lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yasser Sakr, MD, PhD</last_name>
    <phone>01742191538</phone>
    <phone_ext>0049</phone_ext>
    <email>yasser.sakr@med.uni-jena.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum Augsburg, Klinik für Anästhesiologie und Operative Intensivmedizin</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulrich Jaschinski, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Deetjen, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Bad Saarow, Klinik für Intensivmedizin</name>
      <address>
        <city>Bad Saarow</city>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lukas Kreienbühl, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan P. Wirtz, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vivantes Humboldt Klinikum, Klinik für Innere Medizin, Kardiologie und konservative Intensivmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>13509</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn, Klinik für Anästesiologie und Operative Intensivmedizin</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian Putensen, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carsten Weißbrich, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Anästesiologische Klinik</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andreas Wehrfritz, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ixchel Castellonos, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Klinik für Allgemein- und Viszeralchirurgie, Chir. Intensivstation</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefan Utzolino, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lampros Kousoulas, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald, Klinik für Anästhesiologie, Intensiv-, Notfall- und Schmerzmedizin</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian Scheer, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sven-Olaf Kuhn, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen, Klinik für Anästhesiologie, Rettungs- und Intensivmedizin</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Onnen Mörer, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Quintel, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf, Klinik für Intensivmedizin</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephan Kluge, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Axel Nierhaus, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg, Klinik für Anästhesiologie</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Johann Motsch, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Larmann, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Herford, Medizinische Klinik III, Kardiologie</name>
      <address>
        <city>Herford</city>
        <zip>32049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jan Kähler, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Werner, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Herne, Universitätsklinikum der Ruhr-Universität Bochum, Klinik für Anästhesiologie, Operative Intensivmedizin, Schmerztherapie, Palliativmedizin</name>
      <address>
        <city>Herne</city>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Florian Roghmann, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Metin Senkal, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes, Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andreas Meiser, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tanja Meisel, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Innere Medizin I, Kardiologie</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chrsitian Schulze, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julian Westphal, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Klinik für Innere Medizin I, Kardiologie</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yasser Sakr, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julian Westphal, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Klinik für Operative Intensivmedizin</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Norbert Weiler, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ingmar Lautenschläger, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth Krankenhaus, Klinik für Anästhesiologie, Operative Intensivmedizin und Schmerztherapie</name>
      <address>
        <city>Köln</city>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fritz Fiedler, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Petra Tepaß, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig, Interdisziplinäre Internistische Intensivmedizin</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sirak Petros, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorenz Weidhase, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig, Klinik für Anästhesiologie u. Intensivtherapie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Falk Fichtner, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Röder</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig, Klinik und Poliklinik für Neurologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Katja Wartenberg, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominic Michalski, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg, Klinik für Innere Medizin, Kardiologie und Angiologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ivan Tanev, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Schmeisser, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg, Klinik für Anästhesiologie und Intensivmedizin</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Jacob, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Uwe Lodes</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der Johannes-Gutenberg-Universität Mainz, Klinik für Anästhesiologie</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marion Ferner, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Schramm, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der LMU München, Klinik für Anästhesiologie</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sandra Frank, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Stern-Straeter, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU München, Klinik für Anästhesiologie und Intensivmedizin</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Barbara Kapfer, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Martin, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Klinik für Anästesiologie, operative Intensivmedizin und Schmerztherapie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexander Zarbrock, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melanie Meersch, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg, Klinik und Poliklinik für Chirurgie</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hans Jürgen Schlitt, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Dienemann, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 8, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jena University Hospital</investigator_affiliation>
    <investigator_full_name>Yasser Sakr</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Human albumin</keyword>
  <keyword>Sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 18, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT03869385/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

